172 related articles for article (PubMed ID: 36742194)
1. PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population.
Criner G; Martinez F; Gandhi H; Pyenson B; Feigler N; Emery M; Gupta U; Vaduganathan M
J Health Econ Outcomes Res; 2023; 10(1):20-27. PubMed ID: 36742194
[No Abstract] [Full Text] [Related]
2. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler
Lin L; Liu C; Cheng W; Song Q; Zeng Y; Li X; Deng D; Liu D; Chen Y; Cai S; Chen P
Front Pharmacol; 2023; 14():1147985. PubMed ID: 37025493
[No Abstract] [Full Text] [Related]
4. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
[TBL] [Abstract][Full Text] [Related]
5. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study).
Deslee G; Fabry-Vendrand C; Poccardi N; Thabut G; Eteve Pitsaer C; Coriat A; Renaudat C; Maguire A; Pinto T
BMJ Open Respir Res; 2023 Jun; 10(1):. PubMed ID: 37263738
[TBL] [Abstract][Full Text] [Related]
6. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting.
Halpin DMG; Rothnie KJ; Banks V; Czira A; Compton C; Wood R; Tritton T; Massey O; Wild R; Snowise N; Nikitin K; Sharma R; Ismaila AS; Vogelmeier CF
Int J Chron Obstruct Pulmon Dis; 2022; 17():2417-2429. PubMed ID: 36185170
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.
Resta E; Scioscia G; Lacedonia D; Quarato CMI; Panza F; Resta O; Lepore G; Buonamico E; Di Lecce V; Carpagnano GE; Barbaro MPF; Rossi N
BMC Health Serv Res; 2022 Oct; 22(1):1283. PubMed ID: 36284319
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of COPD patients treated with single‑inhaler triple therapy in real-life clinical practice.
Lassan S; Keszegh J; Lassanova M
Bratisl Lek Listy; 2022; 123(1):27-36. PubMed ID: 34967655
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD.
Miravitlles M; Marín A; Huerta A; Carcedo D; Villacampa A; Puig-Junoy J
Int J Chron Obstruct Pulmon Dis; 2020; 15():1643-1654. PubMed ID: 32764910
[TBL] [Abstract][Full Text] [Related]
11. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
[No Abstract] [Full Text] [Related]
12. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
Respir Med; 2019; 158():59-66. PubMed ID: 31605923
[TBL] [Abstract][Full Text] [Related]
13. Clinical Concepts for Triple Therapy Use in Patients with COPD: A Delphi Consensus.
Miravitlles M; Acharya S; Aggarwal B; Fernandes FLA; Dreyse J; Jardim JR; Juthong S; Levy G; Sivori M
Int J Chron Obstruct Pulmon Dis; 2023; 18():1853-1866. PubMed ID: 37662490
[TBL] [Abstract][Full Text] [Related]
14. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.
Rhodes K; Jenkins M; de Nigris E; Aurivillius M; Ouwens M
BMC Med Res Methodol; 2022 May; 22(1):150. PubMed ID: 35614467
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial.
Beeh KM; Scheithe K; Schmutzler H; Krüger S
Int J Chron Obstruct Pulmon Dis; 2024; 19():205-216. PubMed ID: 38249826
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
[TBL] [Abstract][Full Text] [Related]
17. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.
Gaduzo S; McGovern V; Roberts J; Scullion JE; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():391-401. PubMed ID: 30863039
[TBL] [Abstract][Full Text] [Related]
18. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).
Janjua S; Pike KC; Carr R; Coles A; Fortescue R; Batavia M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013381. PubMed ID: 34496032
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
